This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Vote for the Worst Biotech CEO of 2010

Stocks in this article: ELN GENZ XOMA ARNA AMAG AMLN

BOSTON ( TheStreet) -- The winner of the 2010 Worst Biotech CEO of the Year Award goes to ... you decide.

In a new and democratic twist this year, readers of TheStreet's biotech coverage will vote on which chief executive deserves this most ignominious award.

To simplify the voting and help reach a consensus, I've nominated four CEOs who, for various reasons you'll read below, deserve to hold aloft the Nance Trophy amid an angry, insult-throwing crowd of biotech investors. The four Worst Biotech CEO nominees for 2010 are:

Jack Lief of Arena Pharmaceuticals (ARNA), Brian Pereira, Amag Pharmaceuticals (AMAG), Steve Engle of Xoma (XOMA) and Dan Bradbury, Amylin Pharmaceuticals (AMLN).

The Nance Trophy honors David Nance, the former CEO of now bankrupt and defunct Introgen Therapeutics. Few CEOs in biotech did more to hone the fine craft of investor bamboozlement and outright incompetence as Introgen's Nance. Past winners (or should I say losers?) of the Worst Biotech CEO of the Year Award are Elan's (ELN) Kelly Martin in 2008 and Genzyme's (GENZ) Henri Termeer in 2009.

For the 2010 crowning, I'd like readers to cast the deciding votes. Read the following nominating summaries and make your selection in the interactive poll below. Feel free, also, to post comments at the bottom of the story if you feel I left off a CEO deserving of shame.

In a week or so, I'll tally the votes and award the trophy.

Jack Lief, Arena Pharmaceuticals:

For months, Arena and U.S. drug regulators engaged in a debate over preclinical data showing high doses of the company's weight-loss drug lorcaserin caused various tumors in male and female rats. Arena insisted that the "rat cancer" data had no relevance to lorcaserin's use in humans. The FDA disagreed and eventually rejected lorcaserin in large part because of concerns about the unresolved "rat cancer" issue.

Investors were kept entirely in the dark about this important issue, only learning about it after the FDA posted a lorcaserin clinical review two days before its advisory panel meeting in September.

Arena, under Lief's direction, decided that the rat cancer data weren't material and therefore didn't need to be disclosed publicly. The thrashing of Arena's stock price when investors learned about the animal cancer issue suggests otherwise. Arena's stock is down 60% this year -- down 80% from the stock's high in September just before the "rat cancer" issue was eventually disclosed.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs